Effect of Early Syphilis Infection on Plasma Viral Load and CD4 Cell Count in Human Immunodeficiency Virus-Infected Men Results From the FHDH-ANRS CO4 Cohort

Archives of internal medicine (Impact Factor: 17.33). 07/2012; 172(16):1237-1243. DOI: 10.1001/archinternmed.2012.2706
Source: PubMed


Concomitant syphilis and human immunodeficiency virus (HIV) infection is increasingly frequent in industrialized countries.

From a large hospital cohort of HIV-infected patients followed up in the Paris area between 1998 and 2006, we examined the effect of early syphilis on plasma HIV-1 RNA levels and CD4 cell counts. We compared 282 HIV-1-infected men diagnosed as having incident primary or secondary syphilis with 1233 syphilis-free men matched for age (±5 years), sexual orientation, participating center, length of follow-up (±6 months), and immunologic and virologic status before the date of syphilis diagnosis (index date). Increase in viral load (VL) (plasma HIV-1 RNA) of at least 0.5 log or a rise to greater than 500 copies/mL in patients with previously controlled VL during the 6 months after the index date was analyzed, as were CD4 cell count variations and CD4 slope after the index date.

During the 6 months after the index date, VL increase was observed in 77 men with syphilis (27.3%) and in 205 syphilis-free men (16.6%) (adjusted odds ratio [aOR], 1.87; 95% CI, 1.40-2.49). Even in men with a VL of less than 500 copies/mL undergoing antiretroviral therapy, syphilis was associated with a higher risk of VL increase (aOR, 1.52; 95% CI, 1.02-2.26). The CD4 cell count decreased significantly (mean, -28/μL) compared with the syphilis-free group during the syphilis episode (P = .001) but returned to previous levels thereafter.

In HIV-infected men, syphilis was associated with a slight and transient decrease in the CD4 cell count and with an increase in VL, which implies that syphilis may increase the risk of HIV transmission, even in patients receiving antiretroviral therapy and with a VL of less than 500 copies/mL.

Download full-text


Available from: Pierre De Truchis, Oct 03, 2015
27 Reads
  • Archives of internal medicine 07/2012; 172(16):1243-4. DOI:10.1001/archinternmed.2012.3770 · 17.33 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. Oral lesions may constitute the first clinical manifestation in secondary syphilis, but detailed descriptions in HIV-infected individuals are scarce. Objective. To describe the clinical characteristics of oral secondary syphilis in HIV-infected patients and its relevance in the early diagnosis of syphilis. Methods. Twenty HIV/AIDS adult subjects with oral secondary syphilis lesions presenting at two HIV/AIDS referral centers in Mexico City (2003–2011) are described. An oral examination was performed by specialists in oral pathology and medicine; when possible, a punch biopsy was done, and Warthin-Starry stain and immunohistochemistry were completed. Intraoral herpes virus infection and erythematous candidosis were ruled out by cytological analysis. Diagnosis of oral syphilis was confirmed with positive nontreponemal test (VDRL), and, if possible, fluorescent treponemal antibody test. Results. Twenty male patients (median age 31.5, 21–59 years) with oral secondary syphilis lesions were included. Oral lesions were the first clinical sign of syphilis in 16 (80%) cases. Mucous patch was the most common oral manifestation (17, 85.5%), followed by shallow ulcers (2, 10%) and macular lesions (1, 5%). Conclusions. Due to the recent rise in HIV-syphilis coinfection, dental and medical practitioners should consider secondary syphilis in the differential diagnosis of oral lesions, particularly in HIV-infected patients.
    12/2012; 2013. DOI:10.1155/2013/892427
  • [Show abstract] [Hide abstract]
    ABSTRACT: Thirty years after the discovery of HIV, the epidemic continues to spread. Developing new HIV prevention methods to reduce the number of new HIV infections remains a priority. It has recently been shown that antiretroviral (ARV) drugs that have largely contributed to increase life expectancy of HIV-infected people may also have a direct impact on HIV transmission. Two new ART-based HIV prevention methods have proven effective in preventing HIV infection in controlled trials and observational studies: pre-exposure prophylaxis (PrEP) and treatment as prevention (TasP). PrEP consists of ARV drugs to be taken by HIV-negative individuals before potential HIV exposure to reduce the risk of HIV infection, while TasP consists of ARV drugs to be taken by individuals living with HIV to lower the risk of HIV transmission to others. Although these two new prevention tools have proven to be effective at the individual level, their population-level impact remains unclear. Herein in addition to reviewing current PrEP and TasP data, we discuss the potential impact of these two new prevention strategies on the HIV epidemic.
    Medecine sciences: M/S 04/2013; 29(4):373-82. DOI:10.1051/medsci/2013294010 · 0.67 Impact Factor
Show more